NDA 018248 · Fresenius Kabi USA
Oxytocin
Oxytocin · Injection · Oxytocic
Last checked: Nov 19, 2026Latest source record: Sep 20, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1980
Jul 9, 1980
Approved uses
1
Original approval plus efficacy supplements
Registered trials
722
71 Phase 3, 51 recruiting
FAERS reports
2,568
2,294 serious, 145 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 12, 2026.
INDICATIONS AND USAGE IMPORTANT NOTICE: Oxytocin Injection, USP (synthetic) is indicated for the medical rather than the elective induction of labor. Available data and information are inadequate to define the benefits to risks considerations in the use of the drug product for elective induction. Elective induction of labor is defined as the initiation of labor for convenience in an individual with a term pregnancy who is free of medical indications. Antepartum Oxytocin injection (synthetic) is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable, in order to achieve early vaginal delivery for fetal or maternal reasons. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, pre-eclampsia at or near term, when delivery is in the best interest of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) adjunctive therapy in the management of incomplete or inevitable abortion. In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases. Postpartum Oxytocin injection (synthetic) is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage. Antepartum Oxytocin injection (synthetic) is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable, in order to achieve early vaginal delivery for fetal or maternal...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 9, 1980 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
- OXYTOCIN · OXYTOCIN 100USP UNITS/10ML (10USP UNITS/ML) · INJECTABLE, INJECTION · Prescription · TE AP
- OXYTOCIN · OXYTOCIN 300USP UNITS/30ML (10USP UNITS/ML) · INJECTABLE, INJECTION · Prescription
- OXYTOCIN · OXYTOCIN 10USP UNITS/ML (10USP UNITS/ML) · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Oxytocin" as an intervention, any sponsor and status, largest first.
- Intramuscular Oxytocics: A Randomised Control TrialPivotal-lookingCompleted
North Bristol NHS TrustAcademic, hospital or other
NCT02216383 · 5,798 participants · Start Feb 2015 · Primary completion Aug 31, 2018
Drug: Carbetocin; Syntocinon and 1 more · For: Post Partum Haemorrhage
Sites: Bristol, United Kingdom; Gloucester, United Kingdom; Bath, United Kingdom · 5 sites in all
- Oxytocin Via Intramuscular Injection and Intravenous Bolus or Infusion for Prevention of Postpartum HemorrhagePivotal-lookingCompleted
Gynuity Health ProjectsAcademic, hospital or other
NCT01914419 · 4,983 participants · Start Apr 2014 · Primary completion Sep 2015
Drug: Oxytocin · For: Postpartum Hemorrhage
Sites: Alexandria, Egypt; Cairo, Egypt
- Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal DeliveryPivotal-lookingCompleted
University Hospital, AngersGovernment (non-federal)
NCT02302456 · 4,079 participants · Start Feb 2015 · Primary completion Jan 2017
Drug: Tranexamic Acid; Placebo · For: Immediate Postpartum Hemorrhage
Sites: Angers, France
- Saving Lives at Birth in Uganda: Building and Sustaining Capacity of Frontline Health Workers - A Program EvaluationPivotal-lookingCompleted
JhpiegoAcademic, hospital or other
NCT03254628 · 3,440 participants · Start Nov 14, 2014 · Primary completion Dec 31, 2016
Drug: oxytocin and misoprostol · For: Postpartum Hemorrhage; Neonatal Asphyxia
- Reducing Neonatal Morbidity by Discontinuing Oxytocin During the Active Phase of 1st Stage of LaborPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT03991091 · 2,459 participants · Start Jan 17, 2020 · Primary completion Apr 25, 2022
Drug: discontinuation of oxytocin administration; continuation of oxytocin administration · For: Neonatal Morbidity
Sites: Paris, France
- Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCTPivotal-lookingCompleted
University of Alabama at BirminghamAcademic, hospital or other
NCT00790062 · 1,798 participants · Start Nov 2008 · Primary completion Jun 2010
Drug: Oxytocin · For: Uterine Atony; Postpartum Hemorrhage
Sites: Birmingham, Alabama
- Misoprostol for the Treatment of Postpartum HemorrhagePivotal-lookingCompleted
Gynuity Health ProjectsAcademic, hospital or other
NCT00116350 · 1,786 participants · Start Jul 2005 · Primary completion Jan 2008
Drug: Misoprostol; Oxytocin · For: Postpartum Hemorrhage
Sites: Bobo Diolasso, Burkina Faso; Quito, Ecuador; Alexandria, Egypt · 6 sites in all
- Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum HaemorrhagePivotal-lookingTerminated
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT01113229 · 1,721 participants · Start Mar 2010 · Primary completion Jul 2014
Drug: Misoprostol · For: Hemorrhage; Complicating Delivery
Sites: Poissy, France
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- foetal exposure during pregnancy413
- maternal exposure during pregnancy398
- drug ineffective353
- exposure during pregnancy317
- premature baby197
- off label use163
- hypotension160
- premature delivery156
- maternal exposure during delivery112
- low birth weight baby101
- drug exposure during pregnancy99
- postpartum haemorrhage98
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 34 |
| 2005 | 22 |
| 2006 | 54 |
| 2007 | 32 |
| 2008 | 51 |
| 2009 | 40 |
| 2010 | 53 |
| 2011 | 51 |
| 2012 | 50 |
| 2013 | 71 |
| 2014 | 87 |
| 2015 | 89 |
| 2016 | 151 |
| 2017 | 124 |
| 2018 | 158 |
| 2019 | 137 |
| 2020 | 193 |
| 2021 | 188 |
| 2022 | 228 |
| 2023 | 266 |
| 2024 | 186 |
| 2025 | 161 |
| 2026 | 140 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis.
Gallos ID, Yunas I, Devall AJ, et al. · Cochrane Database Syst Rev 2025 · Network Meta-Analysis, Systematic Review
- Prophylactic oxytocin dose following vaginal birth to prevent postpartum hemorrhage: a systematic review and dose-response meta-analysis.
Hébert V, D'Souza R, Santesso N, et al. · Am J Obstet Gynecol 2026 · Systematic Review, Meta-Analysis
- Chronic oxytocin administration stimulates the oxytocinergic system in children with autism.
Moerkerke M, Daniels N, Tibermont L, et al. · Nat Commun 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress.
Heinrichs M, Baumgartner T, Kirschbaum C, et al. · Biol Psychiatry 2003 · Clinical Trial, Comparative Study
- Reduced risk of cesarean delivery with oxytocin discontinuation in active labor: a systematic review and meta-analysis.
Whitley J, Burd J, Doering M, et al. · Am J Obstet Gynecol 2025 · Meta-Analysis, Systematic Review
- Enhancing oxytocin and prolactin levels to address oligogalactia through emotional management and massage in working mothers.
Astuti D, Rahfiludin MZ, Dwidiyanti M, et al. · Narra J 2024 · Randomized Controlled Trial
Sponsor: Fresenius Kabi USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.